If you take action and have not already registered, you will receive periodic updates and communications from Parent Project Muscular Dystrophy.
Please Cosponsor S. 1597, the Patient-Focused Impact Assessment Act!
Dear [Decision Maker],
On June 18th U.S. Senators Roger Wicker, R-Miss., and Amy Klobuchar, D-Minn., introduced the "Patient-Focused Impact Assessment (PFIA) Act" (S.1597) which urges greater transparency of product approval at the Food and Drug Administration (FDA). The measure would require the development of a patient engagement assessment tool, the results of which would be included in the publicly disclosed safety and effectiveness data package of any approved drug. This legislation would allow advocates to see how FDA is incorporating the voice of the patient community during the drug approval process, Its potential impact on victims of rare and fatal diseases, such as Duchenne muscular dystrophy, is instrumental in facilitating the use of necessary and often high-risk medication.
Sincerely,[Your Name] [Your Address] [City, State ZIP][Your Email]